A controversial prevention strategy to treat people at high risk of contracting the AIDS virus with Gilead Sciences Inc.’s Truvada was awarded $11.8 million from the California HIV/AIDS Research Program of the University of California.
Two research teams over the next four years will offer Truvada, counseling and other services to 700 men who have sex with men and to transgender women in Los Angeles, San Diego and Long Beach. A third team in Oakland, Richmond, Berkeley and other East Bay locations will plan a project for young men of color who have sex with men.
It is the largest demonstration project in the United States in pre-exposure prophylaxis, or PrEP, and “TLC+,” a program meant to “locate, engage and retain HIV-infected people in care and start them on life-saving treatment for HIV infection,” according to the University of California.
No comments:
Post a Comment